Meeting
2020 ASCO Virtual Scientific Program
Phase II study of lower-dose pracinostat plus azacitidine safety and efficacy in patients with high/very high-risk myelodysplastic syndromes.
Authors
Ehab L. Atallah
Hematologic Malignancies, Medical College of Wisconsin, Milwaukee, WI
Ehab L. Atallah , Samer K. Khaled , Brenda W. Cooper , Erica D. Warlick , David A. Ramies , Joanne Li , Riccardo Spezia , Silvia Mappa , Michael Kenneth Keng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Myelodysplastic Syndromes (MDS)
Clinical Trial Registration Number
NCT03151304
Citation
J Clin Oncol 38: 2020 (suppl; abstr 7556)
DOI
10.1200/JCO.2020.38.15_suppl.7556
Abstract #
7556
Poster Bd #
329
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Comparison of dose modification strategies to address expected hematologic toxicities in treatment-naïve higher-risk (HR) MDS patients treated with venetoclax + azacitidine.
First Author: Jacqueline Suen Garcia
Poster
2019 ASCO Annual Meeting
Interim results from a phase Ib/II clinical study of the glutaminase inhibitor telaglenastat (CB-839) in combination with azacitidine in patients with advanced myelodysplastic syndrome (MDS).
First Author: Veronica Guerra
Poster
2018 ASCO Annual Meeting
Phase 1b study of venetoclax in combination with azacitidine in patients with treatment-naïve higher-risk myelodysplastic syndromes.
First Author: Chun Yew Fong
Poster
2018 Gastrointestinal Cancers Symposium
Phase II open-label, single-center study evaluating safety and efficacy of pembrolizumab following induction with the hypomethylating agent azacitidine in patients with advanced pancreatic cancer after failure of first-line therapy.
First Author: Rachael A Safyan